Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piera A Merlini

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Blood|August 6, 2003
Vagaries of genetic association studies in myocardial infarctionPier M Mannucci, Diego Ardissino, Piera A Merlini, et al.
Lancet (London, England)|April 3, 2022
Acute coronary syndromesBrian A Bergmark, Njambi Mathenge, Piera A Merlini, et al.
Italian Heart Journal : Official Journal of the Italian Federation of Cardiology|December 14, 2002
Variations in lipoprotein levels after myocardial infarction and unstable angina: the LATIN trialClaudio Fresco, Aldo P Maggioni, Stefano Signorini, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|March 28, 2012
The first Caucasian patient with p.Val122Ile mutated-transthyretin cardiac amyloidosis treated with isolated heart transplantationEnrico Ammirati, Nicola Marziliano, Claudia Vittori, et al.
Journal of the American Heart Association|July 20, 2016
Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50Stephen K Kidd, Marc P Bonaca, Eugene Braunwald, et al.
Circulation|July 22, 2016
Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial InfarctionErin A Bohula, Marc P Bonaca, Eugene Braunwald, et al.
Lancet (London, England)|August 31, 2012
Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trialBenjamin M Scirica, Marc P Bonaca, Eugene Braunwald, et al.
Circulation Research|May 17, 2017
Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart DiseaseAkihiro Nomura, Hong-Hee Won, Amit V Khera, et al.
The New England Journal of Medicine|November 13, 2014
Inactivating mutations in NPC1L1 and protection from coronary heart disease, Nathan O Stitziel, Hong-Hee Won, et al.
The New England Journal of Medicine|March 3, 2016
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease, Nathan O Stitziel, Kathleen E Stirrups, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Blood|August 6, 2003
Vagaries of genetic association studies in myocardial infarctionPier M Mannucci, Diego Ardissino, Piera A Merlini, et al.
Lancet (London, England)|April 3, 2022
Acute coronary syndromesBrian A Bergmark, Njambi Mathenge, Piera A Merlini, et al.
Italian Heart Journal : Official Journal of the Italian Federation of Cardiology|December 14, 2002
Variations in lipoprotein levels after myocardial infarction and unstable angina: the LATIN trialClaudio Fresco, Aldo P Maggioni, Stefano Signorini, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|March 28, 2012
The first Caucasian patient with p.Val122Ile mutated-transthyretin cardiac amyloidosis treated with isolated heart transplantationEnrico Ammirati, Nicola Marziliano, Claudia Vittori, et al.
Journal of the American Heart Association|July 20, 2016
Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50Stephen K Kidd, Marc P Bonaca, Eugene Braunwald, et al.
Circulation|July 22, 2016
Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial InfarctionErin A Bohula, Marc P Bonaca, Eugene Braunwald, et al.
Lancet (London, England)|August 31, 2012
Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trialBenjamin M Scirica, Marc P Bonaca, Eugene Braunwald, et al.
Circulation Research|May 17, 2017
Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart DiseaseAkihiro Nomura, Hong-Hee Won, Amit V Khera, et al.
The New England Journal of Medicine|November 13, 2014
Inactivating mutations in NPC1L1 and protection from coronary heart disease, Nathan O Stitziel, Hong-Hee Won, et al.
The New England Journal of Medicine|March 3, 2016
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease, Nathan O Stitziel, Kathleen E Stirrups, et al.
Pageof 1